Carle Health has become the first hospital running Prenosis’ Sepsis ImmunoScore live in clinical workflow and the first site enrolling patients in the company’s OBSERVE-ARDS study. Prenosis announced the milestones on Monday.
The score reads 22 parameters from the electronic health record, including vital signs, labs and immune biomarkers, to estimate whether a patient has or will develop sepsis within 24 hours. It sits inside Carle’s EHR rather than alongside it, so clinicians see the risk without opening another application.
The Illinois system is not a new customer. Its clinicians and researchers fed data into the studies that built the algorithm, took part in a trial testing whether the tool changed provider judgment, and are now among the first to use it on live patients. Dr. Ben Davis, an emergency physician at Carle Foundation Hospital, said the partnership has run through every stage.
The research side is where the money is. Carle will enroll the first patients in OBSERVE-ARDS, an observational study of acute respiratory distress syndrome, and plans to join a follow-on trial on steroid therapy. Both fall under BARDA contracts supporting precision medicine platforms for medical countermeasures.
Prenosis chief executive Bobby Reddy said Carle’s presence on the company’s Immunix platform lets it enter future trials without a fresh integration. That matters because the company wants up to 40 academic centers in its trial network.
Sepsis kills an estimated 350,000 adults in the U.S. each year, and treatment delays of a few hours measurably worsen survival.
